

# Yiyun Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5629483/publications.pdf>

Version: 2024-02-01

173  
papers

6,672  
citations

66343

42  
h-index

85541

71  
g-index

179  
all docs

179  
docs citations

179  
times ranked

6641  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility study of PET dynamic imaging of [18F]DHMT for quantification of reactive oxygen species in the myocardium of large animals. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 216-225.	2.1	5
2	Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer <sup>11</sup> C-TASP699. <i>Journal of Nuclear Medicine</i> , 2022, 63, 609-614.	5.0	7
3	Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1406-1415.	12.0	6
4	Recently Abstinent Smokers Exhibit Mood-Associated Dopamine Dysfunction in the Ventral Striatum Compared to Nonsmokers: A [11C]-(+)-PHNO PET Study. <i>Nicotine and Tobacco Research</i> , 2022, 24, 745-752.	2.6	5
5	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	3.1	25
6	A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1482-1496.	6.4	16
7	Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory <sup>11</sup> C- $\beta$ -CIT positron emission tomography study in humans. <i>Addiction Biology</i> , 2022, 27, e13123.	2.6	16
8	Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with 18F-SynVesT-1 positron emission tomography imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3482-3491.	6.4	11
9	Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFM. <i>Molecular Imaging and Biology</i> , 2022, , 1.	2.6	0
10	Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , 1.	6.4	8
11	Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[ <sup>11</sup> C]NR2B-Me, (R)-[ <sup>18</sup> F]of-Me-NB1, and (S)-[ <sup>18</sup> F]of-NB1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1398-1409.	4.3	7
12	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with <sup>11</sup> C- $\beta$ -CIT. <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.	0.8	55
13	Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP. <i>Chinese Chemical Letters</i> , 2022, 33, 3543-3548.	9.0	6
14	Feasibility of imaging synaptic density in the human spinal cord using [11C] $\beta$ -CIT PET. <i>EJNMMI Physics</i> , 2022, 9, 32.	2.7	3
15	PET Imaging in Animal Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, .	2.8	4
16	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1348-1357.	2.4	2
17	Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3679-3691.	6.4	4
18	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32

#	ARTICLE	IF	CITATIONS
19	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.	7.9	17
20	Development of [ <sup>89</sup> Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 383-394.	6.4	20
21	Binding of the synaptic vesicle radiotracer [ <sup>11</sup> C]UCB-J is unchanged during functional brain activation using a visual stimulation task. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1067-1079.	4.3	28
22	Simplified Quantification of <sup>11</sup> C-UCB-J PET Evaluated in a Large Human Cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 418-421.	5.0	19
23	First-in-Human Evaluation of <sup>18</sup> F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. <i>Journal of Nuclear Medicine</i> , 2021, 62, 561-567.	5.0	60
24	Quantification of SV2A Binding in Rodent Brain Using [ <sup>18</sup> F]SynVesT-1 and PET Imaging. <i>Molecular Imaging and Biology</i> , 2021, 23, 372-381.	2.6	20
25	First-in-Human Assessment of <sup>11</sup> C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 553-560.	5.0	35
26	PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. <i>Cerebral Cortex</i> , 2021, 31, 2787-2798.	2.9	5
27	Association of A $\beta$ 2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [ <sup>11</sup> C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	6.2	53
28	Assessment of test-retest reproducibility of [ <sup>18</sup> F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1327-1338.	6.4	23
29	Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [ <sup>11</sup> C]PHNO PET. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108514.	3.2	1
30	Comparison of [ <sup>11</sup> C]UCB-J and [ <sup>18</sup> F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	4.3	43
31	Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 627693.	3.5	10
32	Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, 1404-1411.	5.8	25
33	Social Rank, Behavioral Phenotypes and Kappa Opioid Receptor: PET Imaging Studies of Socially Housed Female and Male Monkey Models of Cocaine Use Disorder. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
34	In vivo evidence of lower synaptic vesicle density in schizophrenia. <i>Molecular Psychiatry</i> , 2021, 26, 7690-7698.	7.9	51
35	Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [ <sup>18</sup> F]FPEB PET. <i>NeuroImage</i> , 2021, 238, 118217.	4.2	10
36	Imaging brain cortisol regulation in PTSD with a target for 11 $\beta$ -hydroxysteroid dehydrogenase type 1. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	10

#	ARTICLE	IF	CITATIONS
37	Further Investigation of Synaptic Vesicle Protein 2A (SV2A) Ligands Designed for Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging: Synthesis and Structure-Activity Relationship of Substituted Pyridinylmethyl-4-(3,5-difluorophenyl)pyrrolidin-2-ones. <i>ACS Omega</i> , 2021, 6, 27676-27683.	3.5	2
38	Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13085.	4.1	10
39	First in-human PET study and kinetic evaluation of [ <sup>18</sup> F]AS2471907 for imaging 11 $\beta$ -hydroxysteroid dehydrogenase type 1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 695-704.	4.3	10
40	PET Imaging of Pancreatic Dopamine D <sub>2</sub> and D <sub>3</sub> Receptor Density with <sup>11</sup> C-(+)-PHNO in Type 1 Diabetes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 570-576.	5.0	19
41	Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. <i>Molecular Imaging and Biology</i> , 2020, 22, 832-841.	2.6	23
42	Assessment of a white matter reference region for <sup>11</sup> C-UCB-J PET quantification. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1890-1901.	4.3	77
43	In vivo 5-HT <sub>6</sub> and 5-HT <sub>2A</sub> receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [ <sup>11</sup> C]GSK215083 PET. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111007.	1.8	17
44	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A <sup>11</sup> C-UCB-J positron emission tomography study. <i>Epilepsia</i> , 2020, 61, 2183-2193.	5.1	51
45	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037791.	0.8	1
46	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037792.	0.8	0
47	<sup>11</sup> C-PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043584.	0.8	0
48	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracer PET study. <i>Alzheimer's and Dementia</i> , 2020, 16, e043631.	0.8	0
49	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.	0.8	2
50	Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [ <sup>11</sup> C]UCB-J PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045928.	0.8	1
51	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.	0.8	170
52	PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. <i>Nature Communications</i> , 2020, 11, 2360.	12.8	56
53	Body Mass Index and Age Effects on Brain 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 1124-1131.	2.6	9
54	Synthesis and Preclinical Evaluation of an <sup>18</sup> F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [ <sup>18</sup> F]SynVesT-2. <i>ACS Chemical Neuroscience</i> , 2020, 11, 592-603.	3.5	34

#	ARTICLE	IF	CITATIONS
55	Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. <i>Annals of Neurology</i> , 2020, 87, 329-338.	5.3	112
56	PET imaging of mGluR5 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.	6.2	29
57	Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1200-1204.	5.0	8
58	Inverse changes in raphe and cortical 5-HT <sub>1B</sub> receptor availability after acute tryptophan depletion in healthy human subjects. <i>Synapse</i> , 2020, 74, e22159.	1.2	9
59	Positron Emission Tomography Imaging Evaluation of a Novel 18F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1673-1681.	3.5	10
60	Separating dopamine D2 and D3 receptor sources of [ <sup>11</sup> C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. <i>NeuroImage</i> , 2020, 214, 116762.	4.2	9
61	Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115560.	3.0	6
62	Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J. <i>EJNMMI Research</i> , 2020, 10, 83.	2.5	8
63	Imaging sigma receptors in the brain: New opportunities for diagnosis of Alzheimer's disease and therapeutic development. <i>Neuroscience Letters</i> , 2019, 691, 3-10.	2.1	24
64	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.	2.1	85
65	The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. <i>Biological Psychiatry</i> , 2019, 86, 864-871.	1.3	27
66	Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. <i>Theranostics</i> , 2019, 9, 6991-7002.	10.0	54
67	A Novel <sup>18</sup> F-Labeled Radioligand for Positron Emission Tomography Imaging of 11 $\beta$ -Hydroxysteroid Dehydrogenase (11 $\beta$ -HSD1): Synthesis and Preliminary Evaluation in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2450-2458.	3.5	12
68	Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1952-1965.	6.4	38
69	In Vivo Synaptic Density Imaging with <sup>11</sup> C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1780-1786.	5.0	57
70	Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. <i>Neuropsychopharmacology</i> , 2019, 44, 1720-1727.	5.4	36
71	<sup>18</sup> F-labeled benzylpiperazine derivatives as highly selective ligands for imaging $\beta$ <sub>1</sub> receptor with positron emission tomography. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 425-437.	1.0	2
72	Imaging the Enzyme 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer <sup>11</sup> C-AS2471907 in Human Brain. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1140-1146.	5.0	11

#	ARTICLE	IF	CITATIONS
73	Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. <i>Neuropsychopharmacology</i> , 2019, 44, 1714-1719.	5.4	22
74	A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. <i>Epilepsia</i> , 2019, 60, 958-967.	5.1	45
75	Evaluation of <sup>11</sup> C-LSN3172176 as a Novel PET Tracer for Imaging M <sub>1</sub> Muscarinic Acetylcholine Receptors in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1147-1153.	5.0	17
76	Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation. <i>Molecular Pharmaceutics</i> , 2019, 16, 1523-1531.	4.6	9
77	P4481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1497.	0.8	0
78	ICP40: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTITRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P115.	0.8	0
79	Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107627.	3.2	7
80	Synthesis and <i>in Vivo</i> Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1544-1554.	3.5	70
81	Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical Studies. <i>Molecular Imaging and Biology</i> , 2019, 21, 926-934.	2.6	16
82	Development and In Vivo Evaluation of a <sup>18</sup> F-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1023-1030.	5.0	20
83	Age-Related Change in 5-HT <sub>6</sub> Receptor Availability in Healthy Male Volunteers Measured with <sup>11</sup> C-GSK215083 PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1445-1450.	5.0	34
84	Evaluation of PET Brain Radioligands for Imaging Pancreatic <sup>125</sup> I-Cell Mass: Potential Utility of <sup>11</sup> C-(+)-PHNO. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1249-1254.	5.0	22
85	Novel <sup>18</sup> F-Labeled <sup>18</sup> F-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of <sup>18</sup> F-LY2459989 in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2018, 59, 140-146.	5.0	28
86	The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [ <sup>11</sup> C]FLB457 PET Study. <i>Neuropsychopharmacology</i> , 2018, 43, 1052-1058.	5.4	12
87	Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand <sup>11</sup> C-BMT-136088 for Lung Imaging in Rhesus Monkeys. <i>Journal of Nuclear Medicine</i> , 2018, 59, 327-333.	5.0	16
88	Cortical <sup>125</sup> I-amyloid burden, gray matter, and memory in adults at varying APOE $\epsilon$ 4 risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 207-214.	3.1	28
89	Evaluation of ( <sup>18</sup> F)F-lubatine-specific binding: Implications for reference region approaches. <i>Synapse</i> , 2018, 72, e22016.	1.2	7
90	Kinetic evaluation and test-retest reproducibility of [ <sup>11</sup> C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2041-2052.	4.3	143

#	ARTICLE	IF	CITATIONS
91	P2â€³65: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P832.	0.8	0
92	ICâ€³a€¹83: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. <i>Alzheimer's and Dementia</i> , 2018, 14, P152.	0.8	0
93	PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age. <i>Neuropsychopharmacology</i> , 2018, 43, 2539-2547.	5.4	37
94	InÂVivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. <i>JACC Basic To Translational Science</i> , 2018, 3, 378-390.	4.1	46
95	Bridging from Brain to Tumor Imaging: (S)-(âˆ™)- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice. <i>Molecules</i> , 2018, 23, 702.	3.8	9
96	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.	9.0	304
97	Protective and restorative effects of the traditional Chinese medicine Jitai tablet against methamphetamine-induced dopaminergic neurotoxicity. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 76.	3.7	3
98	Automated radiosynthesis of [18F]FBEM, a sulfhydryl site specific labeling agent for peptides and proteins. <i>Applied Radiation and Isotopes</i> , 2018, 140, 294-299.	1.5	5
99	High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 174-183.	0.8	36
100	A multi species evaluation of the radiation dosimetry of [11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. <i>Nuclear Medicine and Biology</i> , 2017, 47, 56-61.	0.6	8
101	PET Imaging Evaluation of Four <sup>1</sup> Radiotracers in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2017, 58, 982-988.	5.0	24
102	PET imaging of $\alpha 7$ nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1042-1050.	6.4	47
103	1-(4-[ <sup>18</sup> F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging <sup>1</sup> Receptors in the Brain. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4161-4172.	6.4	24
104	Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements. <i>Molecular Imaging and Biology</i> , 2017, 19, 893-902.	2.6	17
105	18 F-Labeled indole-based analogs as highly selective radioligands for imaging sigma-2 receptors in the brain. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3792-3802.	3.0	18
106	PET Imaging for Early Detection of Alzheimerâ€™s Disease. <i>PET Clinics</i> , 2017, 12, 329-350.	3.0	44
107	A modification to improve the reliability of <sup>11</sup> C CN <sup>âˆ™</sup> production in the <sup>18</sup> O GE radiochemistry system. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 592-595.	1.0	5
108	The Search for a Subtype-Selective PET Imaging Agent for the GABA <sub>A</sub> Receptor Complex: Evaluation of the Radiotracer [ <sup>11</sup> C]ADO in Nonhuman Primates. <i>Molecular Imaging</i> , 2017, 16, 153601211773125.	1.4	8

#	ARTICLE	IF	CITATIONS
109	Fluorine-18-Labeled Antagonist for PET Imaging of Kappa Opioid Receptors. <i>ACS Chemical Neuroscience</i> , 2017, 8, 12-16.	3.5	23
110	Quantitative projection of human brain penetration of the H <sub>3</sub> antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. <i>Xenobiotica</i> , 2017, 47, 119-126.	1.1	5
111	Optimized and Automated Radiosynthesis of [18F]DHMT for Translational Imaging of Reactive Oxygen Species with Positron Emission Tomography. <i>Molecules</i> , 2016, 21, 1696.	3.8	18
112	Nicotine and Nicotine Abstinence Do Not Interfere with GABA <sub>A</sub> Receptor Neuroadaptations During Alcohol Abstinence. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 698-705.	2.4	5
113	Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK-6577 in baboons. <i>Synapse</i> , 2016, 70, 112-120.	1.2	4
114	Preclinical Evaluation of <sup>18</sup> F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1448-1453.	5.0	13
115	Quantitative Analysis of Dynamic <sup>123</sup> I-mIBG SPECT Imaging Data in Healthy Humans with a Population-Based Metabolite Correction Method. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1226-1232.	5.0	17
116	First-in-Human Assessment of the Novel PDE2A PET Radiotracer <sup>18</sup> F-PF-05270430. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1388-1395.	5.0	27
117	Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. <i>Epilepsia</i> , 2016, 57, 201-209.	5.1	130
118	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. <i>Psychopharmacology</i> , 2016, 233, 3503-3512.	3.1	101
119	Imaging synaptic density in the living human brain. <i>Science Translational Medicine</i> , 2016, 8, 348ra96.	12.4	343
120	Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. <i>NeuroImage</i> , 2016, 130, 241-247.	4.2	43
121	Receptor Occupancy of the $\mu$ -Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 260-266.	2.5	47
122	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 997-1005.	1.3	83
123	Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system. <i>Neuroscience Letters</i> , 2016, 616, 152-159.	2.1	27
124	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 60-67.	1.5	135
125	Synthesis and Preclinical Evaluation of <sup>11</sup> C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. <i>Journal of Nuclear Medicine</i> , 2016, 57, 777-784.	5.0	197
126	Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. <i>ACS Nano</i> , 2016, 10, 4209-4218.	14.6	103



#	ARTICLE	IF	CITATIONS
127	PET imaging evaluation of [18F]DBT-10, a novel radioligand specific to $\alpha 7$ nicotinic acetylcholine receptors, in nonhuman primates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 537-547.	6.4	20
128	Effects of Jitai Tablet, A Traditional Chinese Medicine, on Spontaneous Withdrawal Symptoms and Modulation of Dopaminergic Functions in Morphine-Dependent Rats. <i>Phytotherapy Research</i> , 2015, 29, 687-694.	5.8	8
129	A Promising PET Tracer for Imaging of $\alpha 7$ Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. <i>Molecules</i> , 2015, 20, 18387-18421.	3.8	13
130	Testâ€Retest Reproducibility of Binding Parameters in Humans with <sup>11</sup> C-LY2795050, an Antagonist PET Radiotracer for the $\mu$ Opioid Receptor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 243-248.	5.0	35
131	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 316.	11.0	304
132	Evaluation of [ 18 F]-(-)-norchlorofluorohomoepibatidine ([ 18 F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. <i>Nuclear Medicine and Biology</i> , 2015, 42, 570-577.	0.6	17
133	Synthesis of [ 18 F]FMISO in a flow-through microfluidic reactor: Development and clinical application. <i>Nuclear Medicine and Biology</i> , 2015, 42, 578-584.	0.6	19
134	Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 747-755.	3.4	25
135	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12468-12473.	7.1	265
136	Measurement of $B_{max}$ and $K_d$ with the Glycine Transporter 1 Radiotracer <sup>18</sup> F-MK6577 using a Novel Multi-Infusion Paradigm. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 2001-2009.	4.3	10
137	Imaging the Cannabinoid CB1 Receptor in Humans with [ <sup>11</sup> C] OMAR: Assessment of Kinetic Analysis Methods, Testâ€Retest Reproducibility, and Gender Differences. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1313-1322.	4.3	79
138	Longitudinal changes of dopamine transporters in heroin users during abstinence. <i>Psychopharmacology</i> , 2015, 232, 3391-3401.	3.1	10
139	Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinsonâ€™s Disease: Involvement of the Dopamine System. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-9.	1.2	15
140	Association of In Vivo $\mu$ -Opioid Receptor Availability and the Transdiagnostic Dimensional Expression of Trauma-Related Psychopathology. <i>JAMA Psychiatry</i> , 2014, 71, 1262.	11.0	67
141	Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. <i>Neuropsychopharmacology</i> , 2014, 39, 866-874.	5.4	43
142	Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1818-1825.	4.3	42
143	An Improved Antagonist Radiotracer for the $\mu$ -Opioid Receptor: Synthesis and Characterization of 11C-LY2459989. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1185-1191.	5.0	26
144	Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising $\beta 1$ receptor imaging agent. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5270-5278.	3.0	17

#	ARTICLE	IF	CITATIONS
145	Preparation of the metabotropic glutamate receptor 5 (mGluR5) PET tracer [ <sup>18</sup> F]FPEB for human use: An automated radiosynthesis and a novel one-pot synthesis of its radiolabeling precursor. <i>Applied Radiation and Isotopes</i> , 2014, 94, 349-354.	1.5	23
146	Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [ <sup>11</sup> C]ABP688 and Magnetic Resonance Spectroscopy. <i>Biological Psychiatry</i> , 2014, 75, 165-171.	1.3	66
147	Reductions in Brain 5-HT <sub>1B</sub> Receptor Availability in Primarily Cocaine-Dependent Humans. <i>Biological Psychiatry</i> , 2014, 76, 816-822.	1.3	50
148	Parametric Imaging and Test-Retest Variability of [ <sup>11</sup> C-(+)-PHNO Binding to D <sub>2</sub> /D <sub>3</sub> Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner. <i>Journal of Nuclear Medicine</i> , 2014, 55, 960-966.	5.0	38
149	Evaluation of the agonist PET radioligand [ <sup>11</sup> C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. <i>NeuroImage</i> , 2014, 99, 69-79.	4.2	54
150	Quantitative Analysis of [ <sup>11</sup> C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain. <i>Neoplasia</i> , 2013, 15, 1347-1353.	5.3	43
151	Synthesis and Evaluation of [ <sup>11</sup> C]-LY2795050 as a $\mu$ -Opioid Receptor Antagonist Radiotracer for PET Imaging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 455-463.	5.0	80
152	Tracer Kinetic Modeling of [ <sup>11</sup> C]AFM, a New PET Imaging Agent for the Serotonin Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1886-1896.	4.3	17
153	Determination of In Vivo $B_{max}$ and $K_d$ for [ <sup>11</sup> C]-GR103545, an Agonist PET Tracer for $\mu$ -Opioid Receptors: A Study in Nonhuman Primates. <i>Journal of Nuclear Medicine</i> , 2013, 54, 600-608.	5.0	31
154	In Vivo Imaging of the Metabotropic Glutamate Receptor 1 (mGluR1) with Positron Emission Tomography: Recent Advance and Perspective. <i>Current Medicinal Chemistry</i> , 2013, 21, 113-123.	2.4	34
155	Synthesis and characterization of two pet radioligands for the metabotropic glutamate 1 (mGlu <sub>1</sub> ) receptor. <i>Synapse</i> , 2012, 66, 1002-1014.	1.2	9
156	Reduced Amygdala Serotonin Transporter Binding in Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2011, 70, 1033-1038.	1.3	79
157	Recovery from chronic spinal cord contusion after nogo receptor intervention. <i>Annals of Neurology</i> , 2011, 70, 805-821.	5.3	87
158	Development of Effective PET and SPECT Imaging Agents for the Serotonin Transporter: Has a Twenty-Year Journey Reached its Destination?. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1499-1526.	2.1	39
159	High-resolution imaging of brain 5-HT <sub>1B</sub> receptors in the rhesus monkey using [ <sup>11</sup> C]P943. <i>Nuclear Medicine and Biology</i> , 2010, 37, 205-214.	0.6	40
160	Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 - 2006. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 889-907.	5.0	11
161	Epibatidine analogues as selective ligands for the $\alpha$ -containing subtypes of nicotinic acetylcholine receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4385-4388.	2.2	21
162	Synthesis of potent and selective serotonin 5-HT <sub>1B</sub> receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4786-4789.	2.2	11

#	ARTICLE	IF	CITATIONS
163	Fluorinated Diaryl Sulfides as Serotonin Transporter Ligands: Synthesis, Structure-Activity Relationship Study, and in Vivo Evaluation of Fluorine-18-Labeled Compounds as PET Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2559-2570.	6.4	59
164	A Positron Emission Tomography Radioligand for the in Vivo Labeling of Metabotropic Glutamate 1 Receptor: (3-Ethyl-2-[ <sup>11</sup> C]methyl-6-quinolinyl)(cis-4-methoxycyclohexyl)methanone. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5096-5099.	6.4	52
165	<sup>11</sup> C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons. <i>Journal of Nuclear Medicine</i> , 2005, 46, 484-94.	5.0	59
166	In vivo affinity of [ <sup>18</sup> F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. <i>Psychopharmacology</i> , 2004, 175, 274-286.	3.1	63
167	A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [ <sup>11</sup> C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([ <sup>11</sup> C]AFM). <i>Nuclear Medicine and Biology</i> , 2004, 31, 543-556.	0.6	38
168	A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter and Biology, 2004, 31, 727-738.	0.6	22
169	The new PET imaging agent [ <sup>11</sup> C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. <i>Nuclear Medicine and Biology</i> , 2004, 31, 983-994.	0.6	20
170	Comparative evaluation of serotonin transporter radioligands <sup>11</sup> C-DASB and <sup>11</sup> C-McN 5652 in healthy humans. <i>Journal of Nuclear Medicine</i> , 2004, 45, 682-94.	5.0	114
171	Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. <i>Molecular Imaging and Biology</i> , 2003, 5, 363-375.	2.6	202
172	Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [ <sup>11</sup> C]5-bromo-2-[2-(dimethylaminomethylphenylsulfanyl)]phenylamine ([ <sup>11</sup> C]DAPA). <i>Nuclear Medicine and Biology</i> , 2002, 29, 741-751.	0.6	23
173	Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [ <sup>11</sup> C]McN 5652, [ <sup>11</sup> C]ADAM, [ <sup>11</sup> C]DASB, [ <sup>11</sup> C]DAPA, and [ <sup>11</sup> C]AFM. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1377-1398.	4.3	111